Cardiovascular death in dialysis patients: Lessons we can learn from AURORA

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 2, 2010, Pages 335-340

  Sniderman, Allan D ^a   Solhpour, Amirreza ^a   Alam, Ahsan ^b   Williams, Ken ^c   Sloand, James A ^d,e  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c KenAnCo Biostatistics   (United States)

^d BAXTER HEALTHCARE CORPORATION   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TROPONIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; CARDIOVASCULAR RISK; DISEASE SEVERITY; DYSLIPOPROTEINEMIA; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTENSION; ISCHEMIA; KIDNEY FAILURE; MICROCIRCULATION; NECROSIS; NEPHROTIC SYNDROME; OSMOSIS; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY; REPERFUSION INJURY; REVIEW; SUDDEN DEATH; ULTRAFILTRATION;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; LIPIDS; MYOCARDIAL REPERFUSION INJURY; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77949328411     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06300909     Document Type: Review

References (43)

1. USRD Annual Data Report 2008, Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, 2008
2. Foley RN, Parfrey PS, Sarnack MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Disease 32[Suppl 3]: S112-S119, 1998
3. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
4. Fellstrom BC, Jardine AG, Schmieder RE, Holdass H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymaniar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
5. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM: ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/tencountry panel. J Intern Med 259: 247-258, 2006
6. Rubins HB, Robins SJ, Collins D, Iranmanesh A, Wilt TJ, Mann D, Mayo-Smith M, Faas FH, Elam MB, Rutan GH, Anderson JW, Kashyap ML, Schectman G: Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 75: 1196-1201, 1995
7. Genest JJ, McNamara JR, Salem DN, Schaefer EJ: Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 67: 1185-1189, 1991
8. Shurraw S, Tonelli M: Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 26: 523-539, 2006
9. de Graaf J, Couture P, Sniderman A: A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nature Clin Endocrinol Metab 4: 608-618, 2008
10. Mudd JO, Boriaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, Kwiterovich PO Jr: Beyond low-density lipoprotein cholesterol: Defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol 50: 1735-1741, 2007
11. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR, AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices: Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC lipoproteins and vascular diseases division working groups on best practices. Clin Chem 55: 407-419, 2009
12. Alaupovic P: The concept of apolipoprotein-defined lipoprotein families and its clinical significance. Curr Atheroscler Rep 5: 459-467, 2003
13. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21: 573-592, 1993
14. Bobik A: Apolipoprotein CIII and atherosclerosis: Beyond effects on lipid metabolism. Circulation 118: 702-704, 2008
15. Sniderman A, Cianflone K, Kwiterovich PO Jr, Hutchinson T, Barre P, Prichard S: Hyperapobetalipoproteinemia: The major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Atherosclerosis 65: 257-264, 1987
16. Attman PO, Samuelsson OG, Moberly J, Johansson AC, Ljungman S, Weiss LG, Knight-Gibson C, Alaupovic P: Apolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis. Kidney Int 55: 1536-1542, 1999
17. Muntner P, Hamm L, Kusek JW, Chen J, Whelton PK, He J: The prevalence of non-traditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140: 9-18, 2004
18. Shoji T, Nishizawa Y, Kawagishi T: Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 131: 229-236, 1997
19. Fytili CI, Progia EG, Panagoutsos SA, Thodis ED, Passadakis PS, Sombolos KI: Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail 24: 623-630, 2002
20. Kwan BCH, Kronenberg F, Beddhu S, Cheung AK: Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18: 1246-1261, 2007
21. Kanbay M, Delibasi T, Kaya A, Aydogan T, Koca C, Akcay A, Duranay M, Yigitoglu R: Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins. Renal Fail 28: 567-571, 2006
22. Sniderman AD, Scantlebury T, Cianflone K: Hypertriglyceridemic hyperapoB: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135: 447-459, 2001
23. Alaupovic P, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Samuelsson O: Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. Kidney Int 69: 1865-1871, 2006
24. Ozsoy RC, Van der Steeg WA, Kastelein JJP, Arisz L, Koopman MG: Dyslipidemia as a predictor of progressive renal failure and the impact of treatment with atorvastatin. Nephrol Dial Transplant 1578-1586, 2007
25. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Weiss L, Alaupovic P: Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 9: 1482-1488, 1998
26. Quaschning T, Mainka T, Nauck M, Rump LC, Wanner C, Kramer-Guth A: Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int Suppl 71: S235-S237, 1999
27. Schabel DE, Morrison HI, Fenton SS: Comparing mortality rates on CAPD/CCPD and hemodialysis. Perit Dial Int 18: 478-484, 1998
28. Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown FG, Bannister K, Wiggins KJ: Association of dialysis modality and cardiovascular mortality in incident dialysis patients. Clin J Am Soc Nephrol 4: 1620-1628, 2009
29. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK: The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Disease 50: 791-802, 2007
30. Paraskevas KI: Statin therapy in peritoneal dialysis patients: Effects beyond lipid lowering. Int Urol Nephrol 40: 165-170, 2008
31. Szeto CC, Wong TYH, Chow K-M, Leung C-B, Li PKT: Are peritoneal dialysis patients with and without renal function equivalent for survival study? Insight from a retrospective review of cause of death. Nephrol Dial Transplant 18: 977-982, 2003
32. Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G: Characteristics of sudden death in hemodialysis patients. Kidney Int 69: 2268-2273, 2006
33. Ritz E, Wanner C: The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol 3: 920-929, 2008
34. Amann K, Wanner C, Ritz E: Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol 17: 2112-2119, 2006
35. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218-223, 2000
36. Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med 357: 1121-1135, 2007
37. McIntyre CW, Burton JO, Selby NM, Leccisotti L, Korsheed S, Baker CS, Camici PG: Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 3: 19-26, 2008
38. Dasselaar JJ, Slart RH, Knip M, Pruim J, Tio RA, McIntyre CW, de Jong PE, Franssen CF: Haemodialysis is associated with a pronounced fall in myocardial perfusion. Nephrol Dial Transplant 24: 604-610, 2009
39. Burton JO, Jeffries HJ, Selby NM, McIntyre CW: Hemodialysis-induced cardiac injury: Determinants and associated outcomes. Clin J Am Soc Nephrol 4: 914 -920, 2009
40. Jones SP, Trocha SD, Lefer DJ: Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol 21: 2059-2064, 2001
41. Gueler F, Park JK, Rong S, Kirsch T, Lindschau C, Zheng W, Elger M, Fiebeler A, Fliser D, Luft FC, Haller H: Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol 170: 1192-1199, 2007
42. Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK: Longer treatment time and slower ultrafiltration in hemodialysis reduced mortality in DOPPS. Kidney Int 69: 1222-1228, 2006
43. Bulfinch T: Age of Fable: Stories of Gods and Heroes, Vol. I and II, New York, Review of Reviews, 1913: 182